Adverse reactions to oncologic drugs: spontaneous reporting and signal detection

Life-threatening dermatologic adverse events in oncology

(2013) Alyx C. Rosen et al.   ANTI-CANCER DRUGS

Bevacizumab and central nervous system (CNS) hemorrhage

(2013) Nathalie Letarte et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Results from the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) Project

(2013) June M. McKoy et al.   DRUG SAFETY

Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors

(2013) Emmanuelle Faye et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pneumothorax as an Adverse Drug Event: An Exploratory Aggregate Analysis of the US FDA AERS Database Including A Confounding By Indication Analysis Inspired by Cornfield's Condition

(2013) Manfred Hauben et al.   International Journal of Medical Sciences

Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy

(2013) Timothy J. Judson et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project

(2013) Beatrice J. Edwards et al.   Journal of Oncology Practice

Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

(2012) David Montani et al.   CIRCULATION

Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database

(2012) Behrooz K. Shamloo et al.   DRUG SAFETY

Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan

(2012) Yuka Horiuchi-Yamamoto et al.   International Journal of Clinical Oncology

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS

(2012) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations

(2012) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations

(2012) Kaori Kadoyama et al.   International Journal of Medical Sciences

Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system

(2012) G. Sarganas et al.   NEURO-ONCOLOGY

Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned

(2012) Ryan M. Carnahan et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Cetuximab infusion reactions: French pharmacovigilance database analysis

(2012) Aurélie Grandvuillemin et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

International Cardioncology Society tackles heart problems in cancer patients

(2011) Carrie Printz   CANCER

Hematologic adverse events associated with temozolomide

(2011) J. Lee Villano et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer

(2011) B. J. Edwards et al.   CLINICAL CANCER RESEARCH

Sources of Information on Lymphoma Associated with Anti-Tumour Necrosis Factor Agents

(2011) Hélène Théophile et al.   DRUG SAFETY

Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication

(2011) Dennis W Raisch et al.   Expert Opinion On Drug Safety

Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology

(2011) Emanuel Raschi et al.   Internal and Emergency Medicine

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

(2011) Kaori Kadoyama et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Accelerated Approval of Oncology Products: The Food and Drug Administration Experience

(2011) John R. Johnson et al.   JNCI-Journal of the National Cancer Institute

Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies

(2011) Alex J Mitchell et al.   LANCET ONCOLOGY

Reliability of adverse symptom event reporting by clinicians

(2011) Thomas M. Atkinson et al.   QUALITY OF LIFE RESEARCH

Disproportionality methods for pharmacovigilance in longitudinal observational databases

(2011) Ivan Zorych et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

(2010) A. M. Evens et al.   ANNALS OF ONCOLOGY

Quality of Methods for Assessing and Reporting Serious Adverse Events in Clinical Trials of Cancer Drugs

(2010) S M Belknap et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mapping the Safety Profile of Biologicals

(2010) Thijs J. Giezen et al.   DRUG SAFETY

Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials

(2010) Bostjan Seruga et al.   JOURNAL OF CLINICAL ONCOLOGY

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

(2010) M. Tuccori et al.   ONCOLOGIST

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate

(2009) D. A. Dorr et al.   CLINICAL CANCER RESEARCH

Venous Thromboembolism in Myelodysplastic Syndrome Patients Receiving Lenalidomide

(2009) Xionghu Yang et al.   CLINICAL DRUG INVESTIGATION

Decision support methods for the detection of adverse events in post-marketing data

(2009) M. Hauben et al.   DRUG DISCOVERY TODAY

Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?

(2009) Elizabeth A. Richey et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Anticancer drugs and central nervous system: Clinical issues for patients and physicians

(2008) Alessandro M. Minisini et al.   CANCER LETTERS

Post‐marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab

(2008) V. González et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY